Our multi-specific immuno-oncology drug ND021 holds the promise to outperform first-generation checkpoint modulators in terms of safety and efficacy.
Pipeline04
Partnered Regionally
Discovery
Preclincal PoC
IND-enabling studies
Phase I
Partner
Partnered Globally
Fully Owned by Numab
ND028
(multi-specific)
Oncology
ND032
(multi-specific)
Oncology
ND021 – Immuno-oncology
ND026 – Inflammation
Multispecific Immuno-Oncology Products
ND021 – Immuno-oncology
ND021 is a next-generation multi-specific immuno-oncology program targeting the tumor-immunity suppressive PD(L)-1 pathway and the tumor-immunity activating 4-1BB/CD137 pathway in a single therapeutic molecule. Targeting these two clinically validated pathways in a combinatorial approach is expected to provide patients suffering from a broad range of cancer types with a unique novel treatment opportunity characterized by an improved benefit-to-risk profile as compared to current standard of care as well as other combinatorial immunotherapy approaches currently in clinical development. The differentiating profile of ND021 is based on its molecular design as a monovalent trispecific antibody fragment aimed at highly effective, while only local activation of a tumor-directed specific immune response. Numab develops this product together with its Chinese partner CStone Pharmaceuticals.
Download poster presentation at AACR Annual Meeting 2020
ND026 – Inflammation
In ND026 is a multi-specific immunomodulatory therapy for inflammatory disorders. Numab develops this program together with its Japanese partner Kaken Pharmaceutical Co., Ltd.
Multispecific Immuno-Oncology Products
Numab is developing multiple proprietary immuno-oncology programs utilizing our versatile, multi-specific MATCH platform. We are combining immune effector functions, immune-checkpoint antagonism and cancer specific targeting to create highly innovative, multi-functional drug candidates designed to bring significant improvement to the lives of cancer patients.
